Total Utang marang Modal Xenetic Biosciences (XBIO)

Xenetic Biosciences - logo grafis emiten XBIO

Xenetic Biosciences (XBIO) is developing cell therapy systems, leveraging licensing fees from its patents. The company competes in the field of chemotherapy enhancement, utilizing its intellectual property to attract investment. The production cycle relies on third-party contractors in the US, which reduces capital expenditures. This daily price chart illustrates a debt-to-equity ratio of 0.00.

Xenetic Biosciences Inc. (XBIO): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 01.11.2026

Rincian metrik lan analitis perusahaan Xenetic Biosciences, Inc. (XBIO)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Xenetic Biosciences Inc.|XBIO - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Xenetic Biosciences|XBIO - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Xenetic Biosciences|XBIO - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku xeneticbio.com|XBIO - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Xenetic Biosciences|XBIO - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Xenetic Biosciences Inc.|XBIO - Kewajiban utang agregat|Utang marang nilai buku Xenetic Biosciences|XBIO - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Xenetic Biosciences|Indikator likuiditas cepet xeneticbio.com
- data bathi resik lan rasio valuasi:
XBIO - Bathi resik
Pambiji fundamental perusahaan:Xenetic Biosciences
Produk dadi Xenetic Biosciences Inc.

The assessment of Xenetic Biosciences (XBIO) margin of safety is based on the ratio of total debt to equity, which determines the degree of financial independence and the risk of bankruptcy during market downturns. By analyzing the trend of the company's total liabilities-to-equity ratio, an investor can see how effectively robotic small-molecule screening enables the scaling of drug development without overloading the balance sheet with excessive leverage.

Analisis pesaing Xenetic Biosciences

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Rasio Total Utang marang Ekuitas CSBR (Champions Oncology)|xbiotech.com - Rasio Utang marang Ekuitas|Total Utang marang Modal CVM (CEL-SCI)|OS Therapies Inc. (OSTX) - Utang marang Modal|RADX - Utang marang Ekuitas|ARTV (Artiva Biotherapeutics, Inc.) - Rasio Utang marang Ekuitas|ANL: Total Utang marang Modal|Utang marang Modal verupharma.com (VERU)|Rasio Total Utang marang Ekuitas TPST|XLO (Xilio) - Utang Agregat marang Modal|Total Utang marang Modal RENB|Koefisien Total Utang marang Modal muraloncology.com|Total Utang marang Modal KAPA (Kairos Pharma)|OKUR - Rasio Total Utang marang Ekuitas|GDTC: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRIS (Curis, Inc.)|APLM: Total Utang marang Modal|THAR (Tharimmune Corporation) - Utang marang Ekuitas|ADVB (Advanced Biomed Inc.) - Total Utang marang Modal|genprex.com (GNPX) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Calidi Biotherapeutics (CLDI)|SBFM - Utang marang Modal|Utang marang Ekuitas Salarius SLRX|Koefisien Total Utang marang Modal Kitov Pharma (PPBT)|AON - Total Utang marang Modal|beigene.com (BGNE) - Rasio Total Utang marang Ekuitas|CKPT: Total Utang marang Modal|ELEV - Koefisien Total Utang marang Modal|ICAD (iCAD Inc.) - Total Utang marang Modal|Utang marang Modal Ikena IKNA|Utang marang Ekuitas Notable Labs, Ltd. (NTBL)|viracta.com - Rasio Utang marang Ekuitas|Total Utang marang Modal MOR (MorphoSys)|NAYA - Rasio Total Utang marang Ekuitas|Ascentage Pharma Group Ltd - Total Utang marang Modal